文献速递艾滋病与性传播感染结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

非洲HIV合并结核治疗女性中DMPA的药代动力学与药效学:标准给药频率的潜在担忧

Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该药代动力学研究评估了接受依非韦伦为基础抗逆转录病毒治疗和利福平为基础结核治疗的HIV/TB共感染非洲女性中DMPA的药代动力学。

要点

  • HIV/TB共感染女性使用依非韦伦和利福平时,DMPA的MPA清除率高于历史对照。
  • 12周时11.9%的女性MPA浓度低于0.1 ng/mL,提示可能存在亚治疗浓度。
  • 研究期间所有女性孕酮浓度均低于1 ng/mL,未发生与DMPA相关的不良事件。

核心结论

  • DMPA与利福平和依非韦伦合用时是安全的,但MPA清除率高于未接受ART的HIV女性,导致12%的女性出现亚治疗浓度,提示可能需要更频繁给药。

研究设计与样本

  • 药代动力学研究,纳入来自5个非洲国家的42名HIV/TB共感染女性,接受依非韦伦为基础抗逆转录病毒治疗和利福平为基础结核治疗。
  • 单次DMPA 150 mg肌内注射后,在第2、4、6、8、10和12周测量血浆MPA浓度和孕酮。
  • 主要结局指标为第12周MPA浓度低于0.1 ng/mL,使用精确95% Clopper-Pearson置信区间评估。

主要发现

  • 42名可评估女性中位年龄32岁,中位CD4计数414 cells/mm3。
  • 5名女性(11.9%;95% CI 4.0-25.6%)在第12周MPA浓度低于0.1 ng/mL,其中1名在第10周MPA浓度低于0.1 ng/mL。
  • 研究期间所有女性孕酮浓度均低于1 ng/mL,未发生与DMPA相关的不良事件。

关键数值与推荐

  • 第12周MPA浓度低于0.1 ng/mL的发生率为11.9%(95% CI 4.0-25.6%)。
  • 所有女性孕酮浓度均低于1 ng/mL。

临床怎么用

  • 对于接受利福平和依非韦伦治疗的HIV/TB共感染女性,使用标准DMPA给药频率时需警惕MPA亚治疗浓度风险。
  • 临床可考虑更频繁的DMPA给药或选择替代避孕方法,但需结合个体情况评估。

局限性

  • 研究样本量较小(42名可评估女性),且为药代动力学研究,临床结局(如意外妊娠)未评估。
  • 历史对照比较可能受人群差异影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective contraception is critical to young women with HIV-associated tuberculosis (TB), as unintended pregnancy is associated with increased perinatal morbidity and mortality. The effects of co-administration of efavirenz and rifampicin on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA) are unknown. We hypothesized that clearance of medroxyprogesterone acetate (MPA) would increase when given with rifampicin and efavirenz, thus increasing risk of ovulation. METHODS: This pharmacokinetics (PK) study assessed DMPA among HIV/TB coinfected women on an efavirenz-based antiretroviral treatment and rifampicin-based TB treatment. Plasma MPA concentrations and progesterone were measured predose (MPA only) and 2, 4, 6, 8, 10, and 12 weeks after a single DMPA 150 mg intramuscular injection. The primary outcome measure, MPA concentration (<0.1 ng/mL) at week 12, was assessed using exact 95% Clopper-Pearson confidence intervals. MPA PK parameters were calculated using noncompartmental analysis. RESULTS: Among 42 PK-evaluable women from 5 African countries, median age was 32 years and median CD4 was 414 cells/mm3. Five women (11.9%; 95% CI, 4.0-25.6%) had MPA <0.1 ng/mL at week 12; of these, one had MPA <0.1 ng/mL at week 10. The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls. There were no adverse events related to DMPA, and progesterone concentrations were <1 ng/mL for all women for the study duration. CONCLUSIONS: DMPA, when given with rifampicin and efavirenz, was safe. MPA clearance was higher than in women with HIV not on ART, leading to subtherapeutic concentrations of MPA in 12% of women, suggesting that more frequent dosing might be needed. CLINICAL TRIALS REGISTRATION: NCT02412436.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mngqibisa R, Kendall MA, Dooley K, et al. Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clin Infect Dis. 2020. PMID: 31504342. doi:10.1093/cid/ciz863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。